Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enveric Biosciences Inc (ENVB) vs GE Vernova Inc (GEV) Price & Performance

Enveric Biosciences IncTrade
GE Vernova IncTrade

Price performance (Past 24H)

Key statistics

Enveric Biosciences Inc vs GE Vernova Inc — how do they compare? Enveric Biosciences Inc trades at $1.38 (market cap $5.32M), while GE Vernova Inc trades at $1,021.35 (market cap $283.57B). The key difference: GE Vernova Inc is far larger — about 53302.6× Enveric Biosciences Inc's market cap, and GE Vernova Inc pays a 0.19% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.

ENVBGEV
Market Cap
$5.32M$283.57B
Sector
HealthTechnology
52-Week High
$17.40$1.17K
52-Week Low
$1.28$547.96
Enterprise Value
$408.82K$276.21B
Dividend Yield
0.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enveric Biosciences Inc

ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.

Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.

GE Vernova Inc

GE Vernova (GEV) stock trades at $1,021.20, down 4.2% over 24 hours, as it approaches its Q2 2026 earnings report on July 22. The technical picture is mixed, with a bearish overall signal but a bullish moving average crossover. Fundamentally, the company shows strong profitability with a 23.81% net margin and robust ROE of 83.23%, though valuation ratios like a P/E of 30.84 and EV/EBITDA of 109.82 appear elevated. Recent earnings have been volatile, with a significant beat in Q1 2026 but a miss in Q3 2025. Analyst sentiment remains overwhelmingly positive, with a 75% buy rating and a consensus price target of $1,260, representing over 23% upside. The company is positioned to benefit from AI-driven power demand and grid modernization, highlighted by recent news coverage and an $11 billion investment push.

The outlook for GEV is cautiously optimistic, driven by its leadership in power infrastructure and exposure to secular growth in AI and data center energy demand. Key opportunities include pricing power from scarce gas turbines, a massive global installed base, and growth in its nuclear segment with the BWRX-300 Small Modular Reactor. Primary risks include execution challenges in its Wind segment, high valuation multiples that leave little room for error, and potential volatility around earnings. The stock's recent decline may present a buying opportunity ahead of earnings for investors bullish on the long-term AI power theme.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB

About GE Vernova Inc

GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.

Read more on GEV